Literature DB >> 14979391

Advances in prevention of mother-to-child HIV transmission.

Chokechai Rongkavilit1, Basim I Asmar.   

Abstract

Advances have been made in the understanding of the pathogenesis of mother-to-child transmission of human immunodeficiency virus (HIV). Most transmission occurs during delivery and after birth throught breastfeeding. For this reason, efforts to interrupt transmission have focused on peripartum period and infant feeding. This includes the use of antiretroviral therapy, elective cesarean section and avoidance of breastfeeding. This review summarizes recent major studies and new development on the prevention of mother-to-child HIV transmission. The application and the impact of such interventions in developing world is discussed. Prevention of mother-to-child transmission of HIV should now be integrated as part of basic maternal and child health services in developing countries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979391     DOI: 10.1007/bf02725662

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  61 in total

1.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

2.  Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades.

Authors:  P Palumbo; B Holland; T Dobbs; C P Pau; C C Luo; E J Abrams; S Nesheim; P Vink; R Respess; M Bulterys
Journal:  J Infect Dis       Date:  2001-09-20       Impact factor: 5.226

3.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.

Authors:  M Lallemant; G Jourdain; S Le Coeur; S Kim; S Koetsawang; A M Comeau; W Phoolcharoen; M Essex; K McIntosh; V Vithayasai
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

6.  Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery.

Authors:  Anne Marcollet; François Goffinet; Ghislaine Firtion; Emmanuelle Pannier; Thiphaine Le Bret; Marie-Laure Brival; Laurent Mandelbrot
Journal:  Am J Obstet Gynecol       Date:  2002-04       Impact factor: 8.661

7.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

8.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.

Authors:  O A Olivero; L M Anderson; B A Diwan; D C Haines; S W Harbaugh; T J Moskal; A B Jones; J M Rice; C W Riggs; D Logsdon; S H Yuspa; M C Poirier
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

9.  Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load.

Authors:  R E Dickover; E M Garratty; S A Herman; M S Sim; S Plaeger; P J Boyer; M Keller; A Deveikis; E R Stiehm; Y J Bryson
Journal:  JAMA       Date:  1996-02-28       Impact factor: 56.272

10.  Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort.

Authors:  L Mandelbrot; J Le Chenadec; A Berrebi; A Bongain; J L Bénifla; J F Delfraissy; S Blanche; M J Mayaux
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.